By – UCLA –
The team will now seek FDA approval to open a clinical trial for the CAR-NKT cell therapy
UCLA researchers have developed a new type of immunotherapy called CAR-NKT cell therapy that, in patient-derived tumor samples, has been shown to be more effective at fighting ovarian cancer than conventional CAR-T cell therapy.
Unlike current cellular immunotherapies that require patient-specific manufacturing and can cost hundreds of thousands of dollars, CAR-NKT cells can be produced off-the-shelf, lowering costs to approximately $5,000 per dose.
The CAR-NKT platform shows promise for treating lung, brain and other solid tumors that have been challenging for CAR-T cell therapies to tackle.
